Pioneering Effective Delivery Solutions: Breaking Barriers in Targeted Cancer Therapy

Click on the animation above to see how our lead candidate therapeutic works

Delivering Where it
​Matters Most 

TransCode Therapeutics focuses on addressing the significant unmet need in oncology, specifically metastatic disease, where cancer spreads to other parts of the body. With no current treatments available for this type of cancer, TransCode utilizes its TTX platform in the metastatic setting to improve treatment outcomes and enable long-term survival possibilities.

Read More

​TransCode Therapeutics believes it has overcome the delivery
challenges of targeted delivery of therapeutics to cancer cells

Lead Therapeutic Candidate, TTX-MC138 targets miRNA-10b widely considered
​the master regulator of cancer progression in 19+ tumor indications

A small, non-coding microRNA called miRNA-10b, is shown to be the master regulator of metastasis in a range of solid tumors

---

Metastatic tumor cells are better equipped to safely travel to other parts of the body and develop metastases in organs different from the organ of origin

Cells in the primary tumor are known to upregulate miRNA-10b which allows metastatic cells to develop, detach, and migrate

---

TransCode’s TTX platform has the potential to treat a variety of
​tumor indications through effective delivery and targeting

Read More